Abbvie Inc.

Abbott Laboratories Corporation

Neurosearch A/s

Abbvie Bahamas Limited

Michael R Schrimpf

Kevin B Sippy

William H Bunnelle

Tao Li

Jianguo Ji

Diana L Nersesian

Lei Shi

Marc J Scanio

Jerome F Daanen

Murali Gopalakrishnan

Karin Rosemarie Tietje

John T Randolph

Gregory A Gfesser

Jennifer M Frost

Ramin Faghih

Anwer Basha

Geoff G Z Zhang

Rodger F Henry

Ming Clinton Yeung

Kevin R Woller

Pramila A Bhatia

Shuang Chen

Xenia Beebe Searle

Dan Peters

Gunnar M Olsen

Elsebet Østergaard Nielsen

Marlon D Cowart

John K Pratt

Chih-hung Lee

Le Wang

Sachin V Patel

Michael J Dart

Dachun Liu

Andrew O Stewart

George S Sheppard

Lisa A Hasvold

Kristine E Frank

Keith F McDaniel

Elsebet Ostergaard Nielsen

Kathleen Mortell

Richard B Toupence

Qingwei I Zhang

Keith Brian Ryther

David J Anderson

Jennifer M Pace

Diana L Donnelly-Roberts

Min Hu

Richard J Perner

Paul J Brackemeyer

Zhiren Xia

Bruce Clapham

Clark A Briggs

Chih-Hung Lee

Huaqing Liu

Philip K Ahring

Michael D Meyer

Michael M Friedman

Tino Dyhring Jørgensen

Maria A Argiriadi

Stanley DiDomenico

Eric C Breinlinger

Michael J Rozema

John Malysz

Steven D Fidanze

Timothy A Esbenshade

Daria Darczak

Marc J C Scanio

Marie P Honore

J Martin Herold

Tino Dyhring Jorgensen

Diana L Schmidt

Stacy A Van Epps

David J Hardee

Ellen Yulin Tsai Chien

Kathleen H Mortell

Wei Qiu

Thomas R Vargo

Matthew P Webster

Andrew J Little

Chang Z Zhu

Daniela Barlocco Cristina

Marc Scanio

Geoff Gz Zhang

Bing Li

Willaim H Bunnelle

Geoff GZ Zhang

Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R, R2, R, R, R, X, X, X, X, X, nad n are as defined herein, pharmaeceutical compositions 2C X, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use. 

Inhibitors of tyrosine kinase 2 mediated signaling

The present application relates to indole and indoline derivatives of formula (I), (II), (III), (IV), (V), or (VI) wherein a, R, R, R, R, R, U, V, W, X, Y, and Z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

Indole and indoline derivatives and methods of use thereof

This invention relates to: (a) compounds and salts thereof that, inter alia, treat pain; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Agents for treating pain and uses thereof

The invention relates to a composition comprising a neuronal nicotinic receptor ligand and an &#x3b1;4&#x3b2;2 positive allosteric modulator, a method of using the same, and a related article of manufacture.

Pharmaceutical compositions and their methods of use

The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.

Azaadamantane derivatives and methods of use

The present invention is directed to methods of treating pain by administering a therapeutically effective amount of an &#x3b1;7 nAChR ligand or a pharmaceutically acceptable salt thereof, to a mammal in need of treatment thereof and to pharmaceutical compositions comprising such a compound or salt.

Methods for treating pain

The invention relates to compounds that are diazahomoadamantane derivatives, compositions comprising such compounds, and methods of using such compounds and compositions.

Diazahomoadamantane derivatives and methods of use thereof

The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein &#x3b1;, R, R, R, and Rare as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

Substituted octahydrocyclopenta[c]pyrroles as calcium channel modulators

The present application relates to indole and indoline derivatives of formula (I) wherein a, R, R, R, h, i, j, m, n, L, Q, and X are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions.

AZA-bridged ring-fused indoles and indolines

The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein L, L, R, R, and Rare as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers

The present application relates to: (a) compounds of Formula (I): and salts thereof, wherein Z, Z, Z, Z, R, R, and Rare as defined in the specification; (b) compositions comprising such compounds and salts; and (c) methods of use of such compounds, salts, and compositions, particularly use as calcium channel inhibitors.

Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers

The present application relates to: (a) compounds of Formula (I): and salts thereof, wherein Z', Z&#x2033;, L, G, R, and Rare as defined in the specification; (b) compositions comprising such compounds and salts; and (c) methods of use of such compounds, salts, and compositions, particularly use as calcium channel blockers.

[object Object]

Growing community of inventors

Grayslake, IL, United States of America

Michael R Schrimpf